Unity Biotechnology UBX

$ 1.16 -0.85%

Quarterly report 2024-Q3
added 11-04-2024

Unity Biotechnology Balance Sheet 2011-2024 | UBX

Annual Balance Sheet Unity Biotechnology

	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	1.26 M	-10.1 M	11.2 M	-37.4 M	-15.3 M	-7.3 M	-89.3 M	-	-	-	-	-
Long Term Debt	-	10.9 M	18.4 M	24.5 M	-	-	-	-	-	-	-	-	-
Long Term Debt Current	3.45 M	3.1 M	4.38 M	4.52 M	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	13.3 M	4.1 M	3.28 M	134 M	-	-	-	-	-
Total Current Liabilities	7.84 M	19.6 M	16.6 M	14.5 M	17.2 M	16.6 M	-	-	-	-	-	-	-
Total Liabilities	37.3 M	68.3 M	65.1 M	73.4 M	30.5 M	20.7 M	11.2 M	138 M	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-484 M	-444 M	-400 M	-	-245 M	-163 M	-86.9 M	-42.2 M	-	-	-	-	-
Total Assets	65.7 M	124 M	125 M	156 M	151 M	181 M	102 M	96.6 M	-	-	-	-	-
Cash and Cash Equivalents	19.8 M	12.7 M	32.9 M	17.8 M	37.5 M	15.4 M	7.3 M	89.7 M	-	-	-	-	-
Book Value	28.4 M	56.1 M	59.6 M	82.9 M	121 M	161 M	90.8 M	-41.5 M	-	-	-	-	-
Total Shareholders Equity	28.4 M	56.1 M	59.6 M	82.9 M	121 M	161 M	-83.1 M	-41.5 M	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Unity Biotechnology

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	20.7 M	21.7 M	22.6 M	23.5 M	-	4.08 M	7.62 M	10.9 M	13.3 M	12.7 M	14.5 M	18.4 M	24.1 M	24.9 M	24.7 M	24.5 M	24.5 M	24.5 M	24.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	33 M	33.8 M	34.9 M	37.3 M	33.1 M	51.6 M	55.6 M	57.5 M	57.8 M	57.7 M	61.8 M	65.1 M	68 M	70.3 M	68.2 M	73.4 M	73.4 M	73.4 M	73.4 M	30.5 M	30.5 M	30.5 M	30.5 M	20.7 M	20.7 M	20.7 M	20.7 M	11.2 M	11.2 M	11.2 M	11.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	216 K	216 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-502 M	-495 M	-490 M	-484 M	-498 M	-483 M	-471 M	-460 M	-446 M	-432 M	-419 M	-400 M	-389 M	-373 M	-355 M	-339 M	-339 M	-339 M	-339 M	-245 M	-245 M	-245 M	-245 M	-163 M	-163 M	-163 M	-163 M	-86.9 M	-86.9 M	-86.9 M	-86.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	47.1 M	53.5 M	58.9 M	65.7 M	69.3 M	101 M	114 M	124 M	136 M	97.6 M	112 M	125 M	126 M	136 M	148 M	156 M	156 M	156 M	156 M	151 M	151 M	151 M	151 M	181 M	181 M	181 M	181 M	102 M	102 M	102 M	102 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	8.9 M	7.58 M	7.43 M	19.8 M	7.88 M	19.1 M	23 M	12.7 M	22.6 M	19.4 M	16.4 M	32.9 M	22 M	13.5 M	26.8 M	17.8 M	17.8 M	17.8 M	17.8 M	37.5 M	37.5 M	37.5 M	37.5 M	15.4 M	15.4 M	15.4 M	15.4 M	7.3 M	7.3 M	7.3 M	7.3 M	89.3 M	-	-	-	940 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	14.1 M	19.8 M	24 M	28.4 M	36.2 M	49.4 M	58.6 M	66.8 M	78.6 M	39.9 M	50.7 M	59.6 M	57.7 M	65.9 M	80 M	82.9 M	82.9 M	82.9 M	82.9 M	121 M	121 M	121 M	121 M	161 M	161 M	161 M	161 M	90.8 M	90.8 M	90.8 M	90.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	14.1 M	19.8 M	24 M	28.4 M	27.7 M	40.8 M	53.4 M	66.8 M	78.6 M	39.9 M	50.7 M	59.6 M	57.7 M	65.9 M	80 M	82.9 M	82.9 M	82.9 M	82.9 M	121 M	121 M	121 M	121 M	161 M	161 M	161 M	161 M	-83.1 M	-83.1 M	-83.1 M	-83.1 M	-41.5 M	-	-	-	-11.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency